23:09 , May 8, 2019 |  BC Extra  |  Company News

Management tracks: Immunocore, Kyn, Engitix

Immunocore Ltd. (Abingdon, U.K.) brought on a third ex-AstraZeneca plc (LSE:AZN; NYSE:AZN) executive, hiring Mohammed Dar as head of clinical development and CMO. Dar was VP, clinical development oncology, R&D at AZ's MedImmune LLC subsidiary....
04:43 , Dec 15, 2018 |  BioCentury  |  Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
19:53 , Nov 2, 2018 |  BC Week In Review  |  Company News

Rigel grants Kissei Asian rights to Tavalisse

Rigel granted Kissei exclusive rights to develop and commercialize Tavalisse fostamatinib for all current and future indications in Japan, China, Taiwan and Korea. Rigel said it has the option to co-develop the product in the...
19:53 , Apr 27, 2018 |  BC Week In Review  |  Company News

Nektar, Takeda partner to evaluate combo therapy for cancer

Nektar Therapeutics (NASDAQ:NKTR) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) partnered to evaluate Nektar's NKTR-214 in combination with Takeda's TAK-659 to treat cancer. The partners will split clinical trials costs. The first trial is expected to...
19:27 , Apr 27, 2018 |  BC Week In Review  |  Financial News

Rigel raises $62.4M in follow-on

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) raised $62.4 million on April 19 through the sale of 16 million shares at $3.90 in a follow-on underwritten by Jefferies, Piper Jaffray, BMO Capital Markets and H.C. Wainwright. The price...
18:49 , Apr 20, 2018 |  Regulatory  |  Regulatory

Rigel gets first FDA approval with Tavalisse

FDA approved an NDA from Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) for Tavalisse fostamatinib to treat chronic idiopathic thrombocytopenic purpura in adults who have had an insufficient response to a previous treatment. The oral spleen tyrosine kinase...
14:45 , Apr 20, 2018 |  Financial News  |  Financial News

Days after first drug approval, Rigel raises $62.4M

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) raised $62.4 million through the sale of 16 million shares at $3.90 in a follow-on underwritten by Jefferies, Piper Jaffray, BMO Capital Markets and H.C. Wainwright. The price is a tiny...
22:51 , Apr 17, 2018 |  BC Extra  |  Company News

Rigel clinches its first approval with ITP drug

FDA approved an NDA from Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) for Tavalisse fostamatinib to treat chronic idiopathic thrombocytopenic purpura in adults who have had an insufficient response to a previous treatment. The oral spleen tyrosine kinase...
14:52 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

Rigel's fostamatinib misses in Phase II for IgA nephropathy

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) said Tavalisse fostamatinib missed the primary endpoint in a Phase II trial to treat IgA nephropathy. Twice-daily 100 and 150 mg doses of fostamatinib each failed to significantly reduce mean proteinuria...